Vorinostat (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vorinostat" in English language version.

refsWebsite

Global rank English rank

23nih.gov

4^th place

13doi.org

2^nd place

4web.archive.org

1^st place

2merck.com

6,464^th place

5,671^st place

2harvard.edu

18^th place

17^th place

2semanticscholar.org

11^th place

8^th place

1europa.eu

68^th place

117^th place

1who.int

195^th place

302^nd place

1hdacis.com

low place

1medscape.com

719^th place

636^th place

1wiley.com

222^nd place

297^th place

1atlasgeneticsoncology.org

low place

1eurekalert.org

3,538^th place

3,083^rd place

1mdsbeacon.com

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1sciencedaily.com

993^rd place

920^th place

atlasgeneticsoncology.org

Castoldi G, Cuneo A (May 2005). "Mycosis fungoides/Sezary's syndrome". Atlas of Genetics and Cytogenetics in Oncology and Haematology. Retrieved 2008-02-15.

clinicaltrials.gov

Clinical trial number NCT01319383 for "The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART" at ClinicalTrials.gov

doi.org

Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. (September 2013). "Development of a histone deacetylase 6 inhibitor and its biological effects". Proceedings of the National Academy of Sciences of the United States of America. 110 (39): 15704–15709. Bibcode:2013PNAS..11015704L. doi:10.1073/pnas.1313893110. PMC 3785767. PMID 24023063.
Marks PA, Breslow R (January 2007). "Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug". Nature Biotechnology. 25 (1): 84–90. doi:10.1038/nbt1272. PMID 17211407. S2CID 12656582.
Friend C, Scher W, Holland JG, Sato T (February 1971). "Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide". Proceedings of the National Academy of Sciences of the United States of America. 68 (2): 378–382. Bibcode:1971PNAS...68..378F. doi:10.1073/pnas.68.2.378. PMC 388942. PMID 5277089.
Breslow R (2016-12-02). "From DMSO to the Anticancer Compound SAHA, an Unusual Intellectual Pathway for Drug Design". In Fischer J, Childers WE (eds.). Successful Drug Discovery. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA. pp. 1–11. doi:10.1002/9783527800315.ch1. ISBN 978-3-527-80031-5. Retrieved 2022-11-18.
Marks PA, Dokmanovic M (December 2005). "Histone deacetylase inhibitors: discovery and development as anticancer agents". Expert Opinion on Investigational Drugs. 14 (12): 1497–1511. doi:10.1038/sj.bjc.6603463. PMC 2360770. PMID 16307490.
Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. (January 2010). "Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer". Journal of Clinical Oncology. 28 (1): 56–62. doi:10.1200/JCO.2009.24.9094. PMC 2799233. PMID 19933908.
Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, et al. (June 2012). "Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome". Journal of Clinical Oncology. 30 (18): 2204–2210. doi:10.1200/JCO.2011.38.3265. PMC 4879705. PMID 22585696.
Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, et al. (October 2009). "A phase 2 study of vorinostat in acute myeloid leukemia". Haematologica. 94 (10): 1375–1382. doi:10.3324/haematol.2009.009217. PMC 2754953. PMID 19794082.
Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM (February 2009). "Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid". AIDS Research and Human Retroviruses. 25 (2): 207–212. doi:10.1089/aid.2008.0191. PMC 2853863. PMID 19239360.
Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM (March 2009). "Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells". The Journal of Biological Chemistry. 284 (11): 6782–6789. doi:10.1074/jbc.M807898200. PMC 2652322. PMID 19136668.
Bouchecareilh M, Hutt DM, Szajner P, Flotte TR, Balch WE (November 2012). "Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency". The Journal of Biological Chemistry. 287 (45): 38265–38278. doi:10.1074/jbc.M112.404707. PMC 3488095. PMID 22995909.
Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, et al. (January 2010). "Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis". Nature Chemical Biology. 6 (1): 25–33. doi:10.1038/nchembio.275. PMC 2901172. PMID 19966789.
Alam MS, Getz M, Haldar K (February 2016). "Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model". Science Translational Medicine. 8 (326): 326ra23. doi:10.1126/scitranslmed.aad9407. PMID 26888431. S2CID 5762569.

eurekalert.org

"Vorinostat shows anti-cancer activity in recurrent gliomas" (Press release). Mayo Clinic. June 3, 2007. Retrieved 2007-06-03.

europa.eu

ema.europa.eu

"Withdrawal Assessment Report for Vorinostat MSD 100 mg Hard Capsules (vorinostat)" (PDF). European Medicines Agency. 23 October 2008. p. 9. Archived from the original (PDF) on 15 September 2016. Retrieved 1 September 2016.

harvard.edu

ui.adsabs.harvard.edu

Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. (September 2013). "Development of a histone deacetylase 6 inhibitor and its biological effects". Proceedings of the National Academy of Sciences of the United States of America. 110 (39): 15704–15709. Bibcode:2013PNAS..11015704L. doi:10.1073/pnas.1313893110. PMC 3785767. PMID 24023063.
Friend C, Scher W, Holland JG, Sato T (February 1971). "Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide". Proceedings of the National Academy of Sciences of the United States of America. 68 (2): 378–382. Bibcode:1971PNAS...68..378F. doi:10.1073/pnas.68.2.378. PMC 388942. PMID 5277089.

hdacis.com

"Vorinostat". HDAC Inhibitors Base.

mdsbeacon.com

Langholtz J, Haehle M (11 January 2012). "Zolinza, Idarubicin, Cytarabine Combination Yields High Response Rates In MDS Patients (ASH 2011)". The MDS Beacon. Archived from the original on 2014-10-30. Retrieved 2012-01-17.

medscape.com

reference.medscape.com

"Zolinza (vorinostat) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 16 February 2014.

merck.com

"Zolinza (vorinostat) Capsules. Full Prescribing Information" (PDF). Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Retrieved 1 September 2016.
"ZOLINZA, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration" (Press release). Merck & Co. June 7, 2006. Archived from the original on September 14, 2006. Retrieved October 6, 2006.

nih.gov

pubmed.ncbi.nlm.nih.gov

Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. (September 2013). "Development of a histone deacetylase 6 inhibitor and its biological effects". Proceedings of the National Academy of Sciences of the United States of America. 110 (39): 15704–15709. Bibcode:2013PNAS..11015704L. doi:10.1073/pnas.1313893110. PMC 3785767. PMID 24023063.
Marks PA, Breslow R (January 2007). "Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug". Nature Biotechnology. 25 (1): 84–90. doi:10.1038/nbt1272. PMID 17211407. S2CID 12656582.
Friend C, Patuleia MC, De Harven E (September 1966). "Erythrocytic maturation in vitro of murine (Friend) virus-induced leukemic cells". National Cancer Institute Monograph. 22: 505–522. PMID 5923328.
Friend C, Scher W, Holland JG, Sato T (February 1971). "Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide". Proceedings of the National Academy of Sciences of the United States of America. 68 (2): 378–382. Bibcode:1971PNAS...68..378F. doi:10.1073/pnas.68.2.378. PMC 388942. PMID 5277089.
Marks PA, Dokmanovic M (December 2005). "Histone deacetylase inhibitors: discovery and development as anticancer agents". Expert Opinion on Investigational Drugs. 14 (12): 1497–1511. doi:10.1038/sj.bjc.6603463. PMC 2360770. PMID 16307490.
Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. (January 2010). "Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer". Journal of Clinical Oncology. 28 (1): 56–62. doi:10.1200/JCO.2009.24.9094. PMC 2799233. PMID 19933908.
Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, et al. (June 2012). "Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome". Journal of Clinical Oncology. 30 (18): 2204–2210. doi:10.1200/JCO.2011.38.3265. PMC 4879705. PMID 22585696.
Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, et al. (October 2009). "A phase 2 study of vorinostat in acute myeloid leukemia". Haematologica. 94 (10): 1375–1382. doi:10.3324/haematol.2009.009217. PMC 2754953. PMID 19794082.
Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM (February 2009). "Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid". AIDS Research and Human Retroviruses. 25 (2): 207–212. doi:10.1089/aid.2008.0191. PMC 2853863. PMID 19239360.
Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM (March 2009). "Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells". The Journal of Biological Chemistry. 284 (11): 6782–6789. doi:10.1074/jbc.M807898200. PMC 2652322. PMID 19136668.
Bouchecareilh M, Hutt DM, Szajner P, Flotte TR, Balch WE (November 2012). "Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency". The Journal of Biological Chemistry. 287 (45): 38265–38278. doi:10.1074/jbc.M112.404707. PMC 3488095. PMID 22995909.
Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, et al. (January 2010). "Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis". Nature Chemical Biology. 6 (1): 25–33. doi:10.1038/nchembio.275. PMC 2901172. PMID 19966789.
Alam MS, Getz M, Haldar K (February 2016). "Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model". Science Translational Medicine. 8 (326): 326ra23. doi:10.1126/scitranslmed.aad9407. PMID 26888431. S2CID 5762569.

ncbi.nlm.nih.gov

Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. (September 2013). "Development of a histone deacetylase 6 inhibitor and its biological effects". Proceedings of the National Academy of Sciences of the United States of America. 110 (39): 15704–15709. Bibcode:2013PNAS..11015704L. doi:10.1073/pnas.1313893110. PMC 3785767. PMID 24023063.
Friend C, Scher W, Holland JG, Sato T (February 1971). "Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide". Proceedings of the National Academy of Sciences of the United States of America. 68 (2): 378–382. Bibcode:1971PNAS...68..378F. doi:10.1073/pnas.68.2.378. PMC 388942. PMID 5277089.
Marks PA, Dokmanovic M (December 2005). "Histone deacetylase inhibitors: discovery and development as anticancer agents". Expert Opinion on Investigational Drugs. 14 (12): 1497–1511. doi:10.1038/sj.bjc.6603463. PMC 2360770. PMID 16307490.
Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. (January 2010). "Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer". Journal of Clinical Oncology. 28 (1): 56–62. doi:10.1200/JCO.2009.24.9094. PMC 2799233. PMID 19933908.
Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, et al. (June 2012). "Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome". Journal of Clinical Oncology. 30 (18): 2204–2210. doi:10.1200/JCO.2011.38.3265. PMC 4879705. PMID 22585696.
Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, et al. (October 2009). "A phase 2 study of vorinostat in acute myeloid leukemia". Haematologica. 94 (10): 1375–1382. doi:10.3324/haematol.2009.009217. PMC 2754953. PMID 19794082.
Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM (February 2009). "Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid". AIDS Research and Human Retroviruses. 25 (2): 207–212. doi:10.1089/aid.2008.0191. PMC 2853863. PMID 19239360.
Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM (March 2009). "Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells". The Journal of Biological Chemistry. 284 (11): 6782–6789. doi:10.1074/jbc.M807898200. PMC 2652322. PMID 19136668.
Bouchecareilh M, Hutt DM, Szajner P, Flotte TR, Balch WE (November 2012). "Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency". The Journal of Biological Chemistry. 287 (45): 38265–38278. doi:10.1074/jbc.M112.404707. PMC 3488095. PMID 22995909.
Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, et al. (January 2010). "Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis". Nature Chemical Biology. 6 (1): 25–33. doi:10.1038/nchembio.275. PMC 2901172. PMID 19966789.

sciencedaily.com

"Cancer drug may help treat human papillomavirus infections". ScienceDaily. 30 November 2018. Retrieved 2018-11-30.

semanticscholar.org

api.semanticscholar.org

Marks PA, Breslow R (January 2007). "Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug". Nature Biotechnology. 25 (1): 84–90. doi:10.1038/nbt1272. PMID 17211407. S2CID 12656582.
Alam MS, Getz M, Haldar K (February 2016). "Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model". Science Translational Medicine. 8 (326): 326ra23. doi:10.1126/scitranslmed.aad9407. PMID 26888431. S2CID 5762569.

web.archive.org

"Withdrawal Assessment Report for Vorinostat MSD 100 mg Hard Capsules (vorinostat)" (PDF). European Medicines Agency. 23 October 2008. p. 9. Archived from the original (PDF) on 15 September 2016. Retrieved 1 September 2016.
"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 56" (PDF). WHO Drug Information. 20 (3): 232. 2006. Archived from the original (PDF) on July 5, 2011. Retrieved 1 September 2016.
"ZOLINZA, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration" (Press release). Merck & Co. June 7, 2006. Archived from the original on September 14, 2006. Retrieved October 6, 2006.
Langholtz J, Haehle M (11 January 2012). "Zolinza, Idarubicin, Cytarabine Combination Yields High Response Rates In MDS Patients (ASH 2011)". The MDS Beacon. Archived from the original on 2014-10-30. Retrieved 2012-01-17.

who.int

apps.who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 56" (PDF). WHO Drug Information. 20 (3): 232. 2006. Archived from the original (PDF) on July 5, 2011. Retrieved 1 September 2016.

wiley.com

onlinelibrary.wiley.com

Breslow R (2016-12-02). "From DMSO to the Anticancer Compound SAHA, an Unusual Intellectual Pathway for Drug Design". In Fischer J, Childers WE (eds.). Successful Drug Discovery. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA. pp. 1–11. doi:10.1002/9783527800315.ch1. ISBN 978-3-527-80031-5. Retrieved 2022-11-18.